- Home
- CYRX vs MREO Comparison
CYRX vs MREO Comparison
Compare CYRX & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYRX
- MREO
- Stock Information
- Founded
- CYRX 1999
- MREO 2015
- Country
- CYRX United States
- MREO United Kingdom
- Employees
- CYRX N/A
- MREO N/A
- Industry
- CYRX Biotechnology: Pharmaceutical Preparations
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- CYRX Health Care
- MREO Health Care
- Exchange
- CYRX Nasdaq
- MREO Nasdaq
- Market Cap
- CYRX 365.5M
- MREO 438.8M
- IPO Year
- CYRX N/A
- MREO N/A
- Fundamental
- Price
- CYRX $7.55
- MREO $1.66
- Analyst Decision
- CYRX Strong Buy
- MREO Strong Buy
- Analyst Count
- CYRX 9
- MREO 5
- Target Price
- CYRX $10.67
- MREO $7.20
- AVG Volume (30 Days)
- CYRX 554.6K
- MREO 3.6M
- Earning Date
- CYRX 08-05-2025
- MREO 08-12-2025
- Dividend Yield
- CYRX N/A
- MREO N/A
- EPS Growth
- CYRX N/A
- MREO N/A
- EPS
- CYRX N/A
- MREO N/A
- Revenue
- CYRX $232,134,000.00
- MREO N/A
- Revenue This Year
- CYRX N/A
- MREO N/A
- Revenue Next Year
- CYRX $9.63
- MREO $52.34
- P/E Ratio
- CYRX N/A
- MREO N/A
- Revenue Growth
- CYRX 11.75
- MREO N/A
- 52 Week Low
- CYRX $4.58
- MREO $1.58
- 52 Week High
- CYRX $9.78
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- CYRX 59.40
- MREO 29.70
- Support Level
- CYRX $7.20
- MREO $2.77
- Resistance Level
- CYRX $7.81
- MREO $3.05
- Average True Range (ATR)
- CYRX 0.40
- MREO 0.18
- MACD
- CYRX 0.01
- MREO -0.06
- Stochastic Oscillator
- CYRX 77.22
- MREO 9.76
About CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).